A phase 1 study of triple‐targeted therapy with BRAF, MEK, and AKT inhibitors for patients with BRAF‐mutated cancers

Documenti analoghi

• Cardiotoxicity of BRAF/MEK inhibitors
  di: Katharina Seuthe, et al.
  Pubblicazione: (2026)
• BRAF/MEK inhibitor rechallenge in advanced melanoma patients
  di: Olivier J. Van Not, et al.
  Pubblicazione: (2024)
• Brugada Phenocopy Induced by BRAF and MEK Inhibitors in a Lung Adenocarcinoma
  di: Leonardo Portolan, et al.
  Pubblicazione: (2024)
• Granulomatous tattoo reaction associated with BRAF/MEK inhibitor therapy for metastatic melanoma
  di: Nasro A. Isaq, et al.
  Pubblicazione: (2024)
• Neoadjuvant BRAF and MEK inhibitor therapy elicits pathological complete response in stage IIIA non‐small cell lung cancer harboring BRAF V600E mutation: A case report
  di: Zhicheng Huang, et al.
  Pubblicazione: (2024)